These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26513538)

  • 21. [The amiodarone-beta blockers combination could represent an alternative treatment in patients at risk for sudden death in which a benefit from implantable defibrillators has not been clearly demonstrated].
    Alboni P
    Ital Heart J Suppl; 2002 Mar; 3(3):337-43. PubMed ID: 12040849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mortality reduction by antiadrenergic modulation of arrhythmogenic substrate: significance of combining beta blockers and amiodarone.
    Ogunyankin KO; Singh BN
    Am J Cardiol; 1999 Nov; 84(9A):76R-82R. PubMed ID: 10568664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The management of ventricular arrhythmias in older patients after CAST.
    Aronow WS
    Drugs Aging; 1995 Feb; 6(2):112-24. PubMed ID: 7711358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Class III antiarrhythmic drugs.
    Singh BN; Ahmed R
    Curr Opin Cardiol; 1994 Jan; 9(1):12-22. PubMed ID: 8199363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of sotalol and d-sotalol on ventricular tachycardia and fibrillation induced by programmed electrical stimulation.
    Aliot E; Sadoul N; De Chillou C
    Eur Heart J; 1993 Nov; 14 Suppl H():74-7. PubMed ID: 7904940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
    Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G
    Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Claudio B; Alice M; Daniel S
    Mini Rev Med Chem; 2018; 18(6):476-482. PubMed ID: 28685702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Class I antiarrhythmic drugs: mechanisms, contraindications, and current indications].
    Pott C; Dechering DG; Muszynski A; Zellerhoff S; Bittner A; Wasmer K; Mönnig G; Eckardt L
    Herzschrittmacherther Elektrophysiol; 2010 Dec; 21(4):228-38. PubMed ID: 21113605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Empiric therapy with beta-blockers.
    Hjalmarson A
    Pacing Clin Electrophysiol; 1994 Mar; 17(3 Pt 2):460-6. PubMed ID: 7513874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapy in inherited and acquired ventricular arrhythmia in structurally normal adult hearts.
    Ortmans S; Daval C; Aguilar M; Compagno P; Cadrin-Tourigny J; Dyrda K; Rivard L; Tadros R
    Expert Opin Pharmacother; 2019 Dec; 20(17):2101-2114. PubMed ID: 31566420
    [No Abstract]   [Full Text] [Related]  

  • 32. Beta adrenergic blockade in the treatment of sustained ventricular tachycardia or ventricular fibrillation.
    Wiesfeld AC; Crijns HJ; Tuininga YS; Lie KI
    Pacing Clin Electrophysiol; 1996 Jul; 19(7):1026-35. PubMed ID: 8823828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation.
    Campbell RW; Furniss SS
    Am J Cardiol; 1993 Aug; 72(4):80A-85A. PubMed ID: 8346732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of Holter ECG guided therapy for ventricular arrhythmias: the ESVEM trial.
    Lazzara R
    Pacing Clin Electrophysiol; 1994 Mar; 17(3 Pt 2):473-7. PubMed ID: 7513876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of drug therapy for sustained ventricular tachyarrhythmias.
    Mitchell LB
    Cardiol Clin; 2008 Aug; 26(3):405-18, vi. PubMed ID: 18538187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiarrhythmic drugs and devices for the management of ventricular tachyarrhythmia in ischemic heart disease.
    Reiffel JA; Reiter MJ; Blitzer M
    Am J Cardiol; 1998 Aug; 82(4A):31I-40I. PubMed ID: 9737652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term outcome of pharmacological and nonpharmacological treatment for ventricular arrhythmias].
    Ohnishi S; Kasanuki H
    J Cardiol; 2000 Mar; 35 Suppl 1():75-84. PubMed ID: 10834174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
    Hohnloser SH; Dorian P; Roberts R; Gent M; Israel CW; Fain E; Champagne J; Connolly SJ
    Circulation; 2006 Jul; 114(2):104-9. PubMed ID: 16818810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
    Connolly SJ; Dorian P; Roberts RS; Gent M; Bailin S; Fain ES; Thorpe K; Champagne J; Talajic M; Coutu B; Gronefeld GC; Hohnloser SH;
    JAMA; 2006 Jan; 295(2):165-71. PubMed ID: 16403928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of the older person with ventricular arrhythmias.
    Aronow WS
    J Am Geriatr Soc; 1999 Jul; 47(7):886-95. PubMed ID: 10404937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.